Our Take
Early validation of a technical approach, not yet evidence of a clinical win: the switchable allogeneic design is differentiated, but the dataset is small, follow-up is short, and the bar to displace oral kinase inhibitors is high.
Why it matters
Relapsed/refractory AML remains a narrow market with limited durable options. Allogeneic manufacturing could solve manufacturing speed for urgent cases, and the switchable CAR design addresses a real safety concern (CD123 expression on healthy cells), but practitioners need longer follow-up data before changing practice.
Do this week
Hematology clinical leadership: flag AVC-201-01 trial enrollment criteria now so you can route eligible R/R AML patients before Phase 1b expands and access becomes gatekeeping.
Early efficacy and safety data from a novel CAR-T design
AvenCell Therapeutics presented updated Phase 1a data from the RevSTAR-123 trial on AVC-201-01 at EHA 2026 (June 13, 2026). The therapy is a CD123-directed allogeneic CAR-T cell therapy, manufactured from healthy donor T cells, with a built-in pharmacological switch that allows CAR activity to be turned on and off by infusing or withholding a separate targeting module.
Among 17 treated patients, heavily pretreated (median four prior therapies, 10 with prior allogeneic stem cell transplant, nine with ELN adverse-risk disease), the trial reported 3 of 8 evaluable patients at the highest dose levels achieving complete remission or complete remission with partial hematologic recovery, including two MRD-negative responses (per the company presentation).
Safety was manageable: cytokine release syndrome occurred in 13 patients but only one grade 3 event. No immune effector cell-associated neurotoxicity (ICANS), no graft-versus-host disease, no treatment-related deaths, and one dose-limiting toxicity at the highest dose.
Addressing a biological problem, not proven clinical superiority
CD123 is an attractive myeloid target but biologically difficult. It is expressed on leukemic blasts and leukemic stem cells but also on normal hematopoietic progenitors and endothelial cells. Continuous CD123 CAR-T activity risks damage to healthy bone marrow. AvenCell's switchable design allows clinicians to modulate CAR activation by controlling infusion of the targeting module, creating a pharmacological brake absent in fixed CAR-T approaches.
The allogeneic format addresses a real clinical urgency. Relapsed/refractory AML patients often cannot wait weeks for autologous T cell manufacturing and may have poor-quality T cells after multiple prior therapies. Off-the-shelf allogeneic CAR-T could compress manufacturing timelines.
However, the market already has alternatives. Astellas' Xospata (gilteritinib), an oral FLT3 inhibitor for FLT3-mutated R/R AML, has Phase III survival data and outpatient dosing but is limited to molecularly defined subgroups. AbbVie's Decnupaz, a CD123-directed antibody-drug conjugate, is approved for blastic plasmacytoid dendritic cell neoplasm and is under Phase III evaluation in AML (per the article). AVC-201-01 will need to demonstrate durable MRD conversion, manageable toxicity, successful bridging to transplant, and longer remission duration to justify the complexity of cellular therapy.
Next steps for hematology teams
This is early validation of a technical concept, not yet a practice-changing therapy. The dataset is small, follow-up is short, and the population is ultra-high-risk (making response interpretation difficult). Practitioners should monitor Phase 1b enrollment data for evidence of dose-response, durability beyond 6-12 months, and any signals of delayed toxicity.
For centers with access to trial enrollment, the switchable CAR design and allogeneic manufacturing timelines may offer an option for R/R AML patients without actionable FLT3 mutations and with poor performance status or prior transplant. However, adoption will depend on clear comparative data against sequential kinase inhibitors or hypomethylating agent combinations, neither of which is available today.